Therefore, low expression of CXCR3 of T lymphocytes in a patient with lung cancer may be a target for exchanging tumors from “cold tumors” to “hot tumors” for improving clinical immunotherapeutic efficacy. This evidence concerns the gene CXCR3 and lung carcinoma.